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ABSTRACT. ***Max 250 words*** (currently 250) 81 
Introduction. Central nervous system (CNS) tumors are a leading cause of death in 82 
children and adolescents. We evaluated the outcome of patients with CNS tumors 83 
enrolled in pediatric phase I trials within the Innovative Therapies for Children with 84 
Cancer (ITCC) consortium.  85 
Methods. Data of patients with solid tumors aged <18 years at enrolment in their first 86 
dose-finding trial between 2000-2014 at eight ITCC centers were collected 87 
retrospectively, including two predictive scores validated in adults: the Royal Marsden 88 
Hospital and MD Anderson Cancer Center scores. Survival analyses were conducted 89 
using long-rank test, Cox regression and Kaplan-Meier methods. 90 
Results. Overall, 114 patients with CNS tumors were assessed. Median age: 10.2 years 91 
(range, 1.0-17.9). Main diagnoses included medulloblastoma/PNET (32.5%) and high-92 
grade gliomas (23.7%). Complete/partial responses were reported in 7.4% patients and 93 
stable disease in 23.8%. In the univariate analysis, performance status ≤80%, no 94 
school/work attendance and ALT/AST above the upper limit of normal correlated with 95 
worse OS. In the multivariate analysis, no factors were significantly associated with OS. 96 
Adult scores were not prognostic of OS. Median Overall Survival (OS) was 11.9 months 97 
with complete/partial response, 11.0 months with stable disease and 3.1 months with 98 
progressive disease (p<0.001) according to RECIST (n=43). 99 
Conclusions. One third of the patients with CNS tumors derived clinical benefit. 100 
Sustained disease stabilization as per RECIST in children with CNS tumors should also 101 
be regarded as a signal of activity in phase I trials. These outcomes will serve as a 102 
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Approximately 16-20% of the cancers diagnosed in children aged 0-14 years in Europe 128 
are central nervous system (CNS) tumors [1]. CNS tumors constitute a leading cause of 129 
cancer-related death in children in Europe, United States and Canada [1–3]. Hence, 130 
there is an unmet need of novel drugs to improve survival outcomes. Dose-finding trials 131 
(phase I and seamless phase I/II trials) are crucial in the evaluation of novel anti-cancer 132 
agents for children, since these studies determine the Recommended Phase II Dose for 133 
a given drug. However, patients with CNS tumors are sometimes excluded from these 134 
trials due to doubts about drug penetration across the blood-brain barrier and/or 135 
concerns raised by previous seizures, steroid requirements and risk of certain neurologic 136 
complications, such as raised intracranial pressure, CNS bleeding or spinal cord 137 
compression. Nonetheless, dose-finding trials are increasingly being incorporated at 138 
earlier time points of treatment-failure for children with advanced solid tumors and a 139 
better understanding of the current landscape of pediatric CNS tumors treated in phase 140 
I trials across Europe will contribute to optimize recruitment and maximize the efficiency 141 
of future phase I trials. 142 
Our main objective was to evaluate the survival outcomes of children and adolescents 143 
with CNS tumors enrolled in phase I trials within the Innovative Therapies for Children 144 
with Cancer (ITCC) European consortium. In addition, we assessed potential prognostic 145 
factors of overall survival (OS) and tested two predictive scores previously validated in 146 
adult cancer patients: the Royal Marsden Hospital (RMH) score and the MD Anderson 147 
Cancer Center (MDACC) score [4–6].  148 
 149 
PATIENTS AND METHODS 150 
The present study is a post-hoc analysis of the patients with CNS tumors included in the 151 
ITCC study evaluating prognostic factors of OS in children and adolescents aged <18 152 
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years at enrolment in their first dose-finding trial [7]. Patients were enrolled between 1st 153 
January 2000 and 31st December 2014 across eight European centers. All phase I trials 154 
had been approved by local institutional review boards. Informed consent by 155 
parents/legal guardians and patients had been obtained for participation to the 156 
corresponding trial.  157 
Only patients who had completed trial screening and had been dosed successfully were 158 
included in this analysis. All diagnoses of refractory or recurrent CNS tumors were 159 
eligible, except for low grade gliomas. Relevant clinical data at baseline and efficacy 160 
outcomes were collected accordingly. Lansky and Karnofsky performance status scales 161 
were converted to Eastern Cooperative Oncology Group (ECOG) scale for calculation of 162 
the MDACC score as follows: Lansky/Karnofsky of 90-100%, 70-80%, 50-60% or 30-163 
40% were equivalent to an ECOG of 0, 1, 2 or 3, respectively.  164 
Outcome data were collected as follows: best response was defined according to 165 
protocol-specific response assessment criteria from day 1 of cycle 1 (C1D1) until best 166 
radiological response at any timepoint (including disease stabilization) or disease 167 
progression, whichever occurred earlier; time-to-progression (TTP) was defined from 168 
C1D1 until disease progression on trial, death or study discontinuation, whichever 169 
occurred earlier; OS was measured from C1D1 until death or last follow-up. Early 170 
mortality rates were also calculated at 30 and 90 days from C1D1. If patients had been 171 
taken off study for reasons other than disease progression, these were collected where 172 
available, as well as the end of study date. In addition, the RMH and MDACC scores 173 
were calculated for patients with data available in all score items (score calculation was 174 
made accounting for 1 point per item). These included albumin <35 g/L, lactate 175 
dehydrogenase (LDH) above the upper limit of normal (ULN) and the presence of ≥3 176 
metastatic sites, for the RMH score [4, 5]; and the aforementioned RMH score items plus 177 
gastrointestinal tumor type and Eastern Cooperative Oncology Group (ECOG) 178 
performance status ≥1, for the MDACC score [6]. 179 
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Descriptive statistics were used to present patients’ characteristics. Categorical data 180 
were compared using Chi-squared test. Survival curves were estimated by the Kaplan-181 
Meier method. Univariate log-rank test was used to compare survival distributions 182 
according to twenty four clinical parameters. Multivariate Cox regression analysis was 183 
performed with those variables identifiable at study entry that correlated with survival in 184 
the univariate analysis. Statistical analyses were conducted with SPSS® version 16.0.  185 
 186 
RESULTS 187 
Baseline patient characteristics. 188 
Out of 248 patients with solid tumors treated across 18 dose-finding trials, 114 (46%) 189 
were diagnosed with CNS tumors (Table 1). For patients with CNS tumors, median age 190 
was 10.2 years (range, 1-17.9) and male to female ratio was 1.15:1. The most frequent 191 
diagnoses were medulloblastoma/primitive neuroectodermal tumor (PNET), high grade 192 
glioma and diffuse intrinsic pontine glioma (DIPG) in 32.5%, 23.7% and 17.5% of cases, 193 
respectively. Approximately half of the patients (48.2%) had metastatic disease at study 194 
entry. The patients had received a median of one line of chemotherapy (range, 0-7) prior 195 
to enrolment. Fifteen patients (13.1%) had not received any chemotherapy at study entry, 196 
including the following diagnoses: DIPG (n=9), ependymoma (n=4), high grade glioma 197 
and neurosarcoma (n=1 each). In 80% cases patients had undergone some debulking 198 
surgery and 93% of patients had received prior radiotherapy. The majority of patients 199 
(67.5%) were treated in trials with single targeted agents (Table 1). Only 5 cases (4.5%) 200 
were discontinued from the trial due to toxicity. 201 
 202 
Response rate and time to progression. 203 
Overall, 109 patients (95.6%) were evaluable for response. Best response included 204 
complete response (CR) in 2.8% of patients, partial response (PR) in 4.6%, stable 205 
disease (SD) in 23.8% and progressive disease (PD) in 68.8% (Table 1). The patients 206 
with CR were diagnosed with medulloblastoma/PNET (n=2) and high grade glioma (n=1). 207 
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The patients with PR were diagnosed with high grade glioma (n=3), 208 
medulloblastoma/PNET (n=1) and atypical teratoid rhabdoid tumor (n=1). The clinical 209 
benefit ratio (CR+PR+SD) was 31.2%. Overall, 88% of patients with CR/PR (n=7/8) and 210 
50% of those with SD (n=13/26) stayed on trial for ≥4 months. Additionally, 63% of 211 
patients with CR/PR (n=5/8) and 23% of those with SD (n=6/26) stayed on trial for ≥6 212 
months. The median TTP for the whole cohort was 1.8 months (95%CI, 1.6-2.0). 213 
 214 
Prognostic factors of overall survival and adult predictive scores. 215 
The median follow-up from C1D1 for the entire cohort was 4.9 months (range, 0.2-96). 216 
The median OS of the whole cohort was 5.4 months (95%CI, 3.8-7.0). Eleven patients 217 
died within 30 days of C1D1: 9.6% (95%CI, 4.2-15.0); and 37 patients died within 90 218 
days of C1D1: 32.5% (95%CI, 23.9-41.1). No drug-related deaths were reported. 219 
In the univariate analysis (log-rank test), factors associated with poorer OS included: 220 
performance status ≤80%, no school/work attendance, alanine aminotransferase (ALT) 221 
or aspartate aminotransferase (AST) above the upper limit of normal (ULN), but within 222 
the maximum limits permitted according to protocol eligibility criteria, and lack of 223 
response or disease stabilization (Table 2).  224 
Objective response and disease stabilization in patients with CNS tumors were 225 
associated with improved survival either when evaluated without distinguishing between 226 
specific response criteria (Table 2), or when evaluated according to RECIST guidelines 227 
(Table 3, Fig. 1). 228 
The multivariate analysis (Cox regression) excluded the response to treatment, because 229 
this cannot be determined at enrolment and therefore does not constitute a baseline 230 
prognostic factor. No clinical variables were significantly associated with OS in the 231 
multivariate analysis, although performance status and school/work attendance were 232 
close to the 95% significance level: p=0.059 and p=0.063, respectively (Table 2). 233 
The RMH and MDACC scores were calculated in 59 (51.8%) and 57 (50%), respectively. 234 





Despite numerous clinical trials, treatment options for relapsed CNS tumors are generally 238 
limited and survival outcomes across tumor types are still modest, with 5-year survival 239 
rates of children with CNS tumors in Europe of 57.5% [1]. Hence, novel therapies are 240 
still needed for recurrent/refractory pediatric CNS tumors and the fact that nearly half of 241 
all patients included in the pediatric ITCC phase I trials were children with CNS tumors 242 
reflects this medical need [7], as well as the feasibility of enrolling these patients in 243 
paediatric phase I trials. 244 
Adults with CNS tumors have historically been excluded from phase I trials due to their 245 
poor prognosis, concomitant drug interactions, concerns about excessive toxicities and 246 
limited efficacy. For instance, in a multicentric review of 2,182 adult cancer patients 247 
participating in phase I trials, the rate of patients with CNS tumors was <7% and in a 248 
large institutional cohort of 1,181 adult cancer patients in phase I trials only 12 (0.01%) 249 
had CNS tumors [6, 8]. Notwithstanding, adults with CNS tumors enrolled in phase I trials 250 
seem to have a survival advantage compared to those not enrolled [9]. Since there is a 251 
paucity of data in children and adolescents with CNS tumors for reference, we assessed 252 
the outcomes of 114 children and adolescents with CNS tumors who participated in a 253 
dose-finding trial. This is to date the largest series of its kind. 254 
Patients with CNS tumors represented 46% of the population enrolled in dose-finding 255 
trials across 8 large pediatric oncology units in 4 European countries over a period of 15 256 
years [7]. This is relatively similar to that reported in a former review of pediatric phase I 257 
trials in the United States conducted between 1992 and 2005, where 35% of the patients 258 
had brain tumors [10].  259 
The age and gender distributions in our sample are similar to those previously reported 260 
in two European centers reviewing the participation in pediatric phase I and phase II 261 
trials, with a median age of 10-12 years and a mild predominance of male patients [11, 262 
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12]. Trial participation was deemed safe, with only 4.5% of cases being discontinued 263 
because of toxicity and no reported deaths attributed to the study drug. 264 
As regards efficacy, approximately one third of the patients with CNS tumors enrolled in 265 
a phase I trial derived some clinical benefit (CR+PR+SD). Patients assessed according 266 
to RECIST v1.0 or v1.1 were analyzed jointly for study purposes, based on the fact that 267 
the main differences between RECIST v1.0 and v1.1 relate to the maximum number of 268 
target lesions and evidence from a cohort of more than 6,500 adults with metastatic 269 
cancer who were evaluated according to both versions showed that the reduction in the 270 
number target lesions, as per v1.1, did not affect the overall response rate and only 271 
affected minimally the PFS [13]; therefore simplifying the measurements, but without 272 
reducing the prognostic value of the response criteria. The response rates observed in 273 
our pediatric and adolescent cohort are comparable to those reported in previous reviews 274 
of pediatric phase I trials, showing objective responses in 3.8-9.6% of cases and disease 275 
stabilization in 17-37.7% [10–12, 14]. Likewise, the median TTP and OS in our cohort 276 
are similar to those previously reported: 1.3-2.8 months for TTP and 3.6-8.5 months for 277 
OS [10–12, 15]. However, these studies did not analyze efficacy in the subset of patients 278 
with CNS tumors separately. Hence, our findings could serve as a suitable reference for 279 
evaluation of early signs of activity in children and adolescents with CNS tumors in future 280 
phase I trials. 281 
In terms of survival outcomes, as it is to be expected, we observed that response 282 
correlates with survival. In adults enrolled in phase I trials, it has been shown a near-283 
linear relationship between tumor shrinkage assessed by RECIST and OS [16]. In 284 
pediatric phase I trials, we have previously shown that the grade of tumor shrinkage, by 285 
RECIST, also correlates with the duration of response and the OS [17]. But importantly, 286 
in agreement with previous reports [7, 17], in our cohort patients with CNS tumors who 287 
achieved disease stabilization had survival rates comparable to those with objective 288 
responses. These findings suggest that novel targeted therapies, even if they cannot 289 
induce significant tumor shrinkage, may halt tumor growth sufficiently as to confer a 290 
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survival advantage for some patients. Therefore sustained disease stabilization in 291 
pediatric CNS tumors should also be regarded as a “signal of activity” in early phase 292 
trials of novel agents. 293 
As regards other prognostic factors, we have previously shown that some indicators of 294 
the patient´s well-being, such as performance status and school/work attendance at 295 
enrolment, were associated with OS in pediatric phase I trials [7]. In the subset of patients 296 
with CNS tumors, performance status ≤80% and no school/work attendance at enrolment 297 
were associated with worse OS in the univariate analysis and there was a trend towards 298 
poorer OS in the multivariate analysis. Conversely, the association of elevated ALT and 299 
AST with worse OS in the univariate analysis might be anecdotal and should be regarded 300 
with caution. In addition, two clinical scores previously validated in adult cancer patients 301 
as good predictors of survival were assessed in this patient population: the RMH score 302 
and the MDACC score [4–6]. Both scores were suboptimal in our cohort of patients with 303 
CNS tumors. Likewise, the RMH score did not correlate with survival in 55 adults with 304 
CNS tumors enrolled in phase I trials [9]. These findings illustrate the lack of reliable 305 
indicators of OS and highlight the need to identify prognostic factors specific for children 306 
and adolescents with CNS tumors to optimize patient selection for phase I trials.  307 
Limitations of this study to be acknowledged include its retrospective nature, the use of 308 
different response assessment criteria depending on the trial and the lack of a validation 309 
cohort.  310 
In summary, this study is the largest review of children and adolescents with CNS tumors 311 
participating in a dose-finding trial and is representative of the European drug 312 
development landscape over the past 15 years. Overall, CNS tumors represented half 313 
of the diagnoses of children enrolled in phase I trials across Europe. Up to one third of 314 
the patients with CNS tumors derived clinical benefit from the phase I trial. Response 315 
was associated with improved OS. Interestingly, survival rates in patients with disease 316 
stabilization as best response were comparable to those with objective responses. These 317 
response rates and survival outcomes will serve as a reference for future phase I trials 318 
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for children and adolescents with CNS tumors. Performance status ≥90% and 319 
school/work attendance at study entry were associated with improved OS in the 320 
univariate analysis, but more specific prognostic factors are still needed to optimize the 321 
selection of patients with CNS tumors in pediatric phase I trials. Overall this study shows 322 
that entering children/adolescents with CNS tumors in phase I trials is feasible, safe and 323 
offers potential benefit for the patients. 324 
  325 
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FIGURE CAPTIONS 397 
Fig. 1 Kaplan-Meier curves of overall survival according to radiological response as per 398 
Response Evaluation Criteria In Solid Tumors (RECIST); n=43 399 
Fig. 2 Kaplan-Meier curves of Overall Survival for Royal Marsden Hospital score (A) and 400 
MD Anderson Cancer Center score (B) 401 
Fig. 1 Kaplan-Meier curves of Overall Survival according to radiological response as 
per Response Evaluation Criteria In Solid Tumors (RECIST); n=43 
 
Fig. 2 Kaplan-Meier curves of Overall Survival for Royal Marsden Hospital score (A) 




Table 1: Demographics of the study population (N=114). 
Items Number (%) 
BASELINE PATIENT CHARACTERISTICS 


















High Grade Glioma 
DIPG1 
Ependymoma  




































≥ 3 lines 
 






























Single targeted agent  
Single cytotoxic agent  
>1 targeted agent  
>1 cytotoxic agent  






































1 DIPG patients were only eligible if they had experienced progression after radiotherapy prior to 
enrolment; 2 Other CNS tumors include: ATRT (n=8), pineoblastoma and neurosarcoma (n=2 each), 
posterior fossa tumor NOS and glioblastoma/undifferentiated sarcoma (n=1 each); 3 Only tumor types for 
which ASCT is generally accepted as part of their treatment, either at diagnosis or at relapse, were 
included (i.e. medulloblastoma/sPNET, pineoblastoma, ATRT); 4 Other response criteria included: 
McDonald (n=8), RANO (n=6) or protocol-specific (n=2); 5 Including patients with non-measurable disease 
who achieved non-CR/non-PD; 6 Other reasons for study discontinuation included: completion of trial 
protocol (n=3), complete response (n=2), error in administration (n=1). 
ASCT: autologous stem cell transplant; ATRT: atypical teratoid rhabdoid tumor; CNS: central nervous 
system; DIPG: diffuse intrinsic pontine glioma; GTR: gross total resection; MDACC: MD Anderson Cancer 
Center; PNET: primitive neuroectodermal tumor; RANO criteria: Response Assessment in Neuro-Oncology 
criteria; RECIST: Response Evaluation Criteria In Solid Tumors; RMH: Royal Marsden Hospital; WHO 












Table 2: Median overall survival, log-rank test for univariate analysis and Cox regression 
for multivariate analysis according to clinical and analytical factors. 
Not available/evaluable 5 (-) 













































Log-rank test (p 
value)2 
Cox regression (p 
value)2 
BASELINE PATIENT CHARACTERISTICS 










1.3 – 7.0 
3.3 – 8.2 









3.2 – 8.8 
3.2 – 7.3 0.841 - 
Time from diagnosis to Cycle 1 Day 1: 






3.5 – 5.1 
5.0 – 10.1 0.094 - 







4.9 – 8.5 








0.6 – 4.8 
4.5 – 9.3 0.011 0.063 







3.9 – 7.0 








3.1 – 6.7 
4.1 – 8.0 0.780 - 
LAB VALUES AT BASELINE 
Anemia:4 






3.9 – 6.9 
<0.1 – 14.4 0.723 - 
Neutropenia:4 






4.0 – 7.7 
<0.1 – 8.8 0.120 - 
Platelets (x109/L): 






3.9 – 7.7 
<0.1 – 7.5 0.168 - 
Creatinine: 






3.7 – 7.2 
N/A 0.394 - 
Total Bilirubin: 






3.7 – 7.8 
1.2 – 2.1 0.840 - 
Albumin (g/L): 






3.5 – 7.5 
0.4 – 3.2 0.266 - 
Alanine aminotransferase (ALT): 






3.8 – 7.8 
0.1 – 6.1 0.029 0.553 
Aspartate aminotransferase (AST): 






3.7 – 8.0 
1.1 – 5.2 0.039 0.229 
Lactate dehydrogenase (LDH): 






1.9 – 9.1 
3.6 – 7.3 0.446 - 
PREVIOUS TREATMENTS 
Previous chemotherapy: 
114 0-2 lines 





3.7 – 6.8 
1.0 – 10.0 0.860 - 
Previous surgery: 









2.5 – 6.1 
2.1 – 8.8 









3.6 – 8.9 
3.5 – 6.3 0.137 - 
Previous autologous stem cell transplant :6 
 1 Patients for whom the item was not applicable/available were excluded from the univariate analysis and 
re-calculated sample sizes were added as applicable; 2 Significant p values (<0.05) are represented in 
bold; 3 Lansky and Karnofsky scales were used interchangeably, performance statuses reported as per 
ECOG scale were converted to Lansky/Karnofsky as described in the Methods section; 4 Grading as per 
CTCAE v4.03; 5 Abnormal lab parameters at baseline were within the limits permitted per protocol and all 
patients were successfully enrolled in their respective trials; 6 Only tumor types for which ASCT is 
generally accepted as part of their treatment, either at diagnosis or at relapse, were included (i.e. 
medulloblastoma, PNET, pineoblastoma and ATRT); 7 Including patients with non-CR/non-PD; 8 Not 
included in the multivariate analysis of prognostic factors, because tumour response cannot be known at 
baseline.  
ATRT: atypical teratoid rhabdoid tumor; CR: complete response; CTCAE: Common Terminology Criteria 
for Adverse Events; GTR: gross total resection; N: sample size for each variable; N/A: not applicable; OS: 
overall survival; PD: progressive disease; PR: partial response; PNET: primitive neuroectodermal tumor; 
SD: stable disease; ULN: upper limit of normal; 95%CI: 95% confidence interval. 
 
Table 3: Median overall survival and log-rank test for univariate analysis according to 
best response assessed by RECIST guidelines (v1.0 or v1.1). 

















9.7 – 14.1 
2.9 – 19.0 
2.4 – 3.8 
<0.001 
 
1 Two patients who were not evaluable were excluded from the univariate analysis; 2 Significant p values 
(<0.05) are represented in bold; 3 Including patients with non-Complete Response/non-Progressive 
Disease.  








0.6 – 12.8 














2.7 – 5.9 
4.1 – 6.7 
8.4 – 12.6 0.696 - 










8.5 – 15.2 
7.3 – 21.8 
2.9 – 4.4 
<0.001 N/A8 
CLINICAL SCORES 













3.4 – 10.4 























3.8 – 11.0 
3.4 – 8.2 
3.9 – 4.3 




 SUPPLEMENTAL MATERIAL 
Suppl Table 1: List of phase I trials included in the study. 
# Study drug Category Mechanism 
1 AT9283 Targeted Aurora kinase inhibitor 
2 Dabrafenib Targeted B-RAF inhibitor 
3 Dalotuzumab +/- 
Ridaforolimus 
Targeted Antibody anti-IGFR1 +/- mTOR 
inhibitor 
4 Erlotinib Targeted EGFR inhibitor 
5 Figitumumab Targeted Antibody anti-IGFR1 
6 LDE225 (sonidegib) Targeted SHH inhibitor 
7 LEE011 (ribociclib) Targeted CDK4/6 inhibitor 
8 LDK378 (ceritinib) Targeted ALK inhibitor 
9 Regorafenib Targeted Multi-kinase inhibitor 
10 Ridaforolimus Targeted mTOR inhibitor 
11 Vemurafenib Targeted B-RAF inhibitor 
12 Rapamycin/Irinotecan Targeted/Cytotoxic mTOR inhibitor / Topoisomerase 
inhibitor 
13 Cisplatin/Temozolomide Cytotoxic DNA cross-link / DNA alkylation 
14 Liposomal daunorubicin Cytotoxic Inhibition of DNA synthesis  
15 Liposomal doxorubicin Cytotoxic Inhibition of DNA synthesis 
16 Oxaliplatin Cytotoxic Inhibition of DNA synthesis 
17 Plitidepsin Cytotoxic JNK and p38 MAPK activation 
18 Topotecan/temozolomide Cytotoxic Topoisomerase inhibitor / DNA 
alkylation 
 
